Cover Image
市場調查報告書

美國的抗糖尿病藥物市場預測

US Antidiabetics Drug Market Outlook 2022

出版商 KuicK Research 商品編碼 453761
出版日期 內容資訊 英文 120 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的抗糖尿病藥物市場預測 US Antidiabetics Drug Market Outlook 2022
出版日期: 2017年03月01日 內容資訊: 英文 120 Pages
簡介

本報告提供美國的抗糖尿病藥物市場相關調查分析,糖尿病的流行病學,抗糖尿病藥物市場概要,主要上市產品,生技仿製藥胰島素,抗糖尿病藥物市場未來發展預測等系統性資訊。

第1章 抗糖尿病藥物:糖尿病的收銀機麵條

  • 糖尿病的徵兆
  • 所謂抗糖尿病藥物

第2章 糖尿病的管理的歷史

  • 從糖尿病到胰島素
  • 對口服糖尿病治療藥的歷史途徑

第3章 糖尿病的治療

  • 糖尿病的非藥理學的處置方法
  • 糖尿病的藥理學性方法

第4章 抗糖尿病藥物的目錄

  • 抗糖尿病藥物:口服藥
    • 雙胍類(Biguanides )
    • 胰島素增敏劑 (TZD)
    • 磺醯尿素類
    • Meglitinides
    • α-Glucosidase抑制劑
    • DPP-4抑制劑
    • 膽汁酸抑製藥 (BAS)
    • 多巴胺促效劑-2

第5章 抗糖尿病藥物:注射藥

  • 胰島素
  • 非胰島素替代藥

第6章 美國的糖尿病的流行病學

  • 第一型、第二型糖尿病的盛行率
  • 第一型、第二型糖尿病相關的經濟負擔

第7章 美國的抗糖尿病藥物市場概要

  • 美國的抗糖尿病藥物 (注射藥) 市場趨勢
  • 美國的抗糖尿病藥物 (口服藥) 市場趨勢
  • 糖尿病的推薦趨勢

第8章 美國:已上市的主要的抗糖尿病藥物

第9章 美國的生技仿製藥市場

  • 概要
  • 生技仿製藥胰島素的影響

第10章 美國的抗糖尿病藥物市場動態

  • 推動因素
  • 主要課題

第11章 美國的抗糖尿病藥物市場未來發展預測

第12章 競爭情形

  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Eli-Lilly
  • Johnson & Johnson
  • Merck
  • Novartis
  • Novo Nordisk
  • Sanofi
  • 武田藥品工業
目錄

"US Antidiabetics Drug Market Outlook 2022" report gives clinical and non-clinical insight on trends associated with the development of Antidiabetics drug market in US. Report helps to identify the diabetes epidemiology ( Prevalence of Type 1 & 2 Diabetes) in the US market along with the associated economic burden and productivity loss.

Diabetes rates in the US have been increasing substantially. While the number of people with diabetes in the US continues to grow, the number of new cases has been declining since 2009, after decades of increases in new cases. Although the numbers are not growing dramatically each year, they are still alarmingly high. About 8.1 Million people with diabetes do not have knowledge that they have diabetes as prediabetes and type2 diabetes have few physical symptoms.

Diabetes mellitus being the most common chronic disease with high mortality, morbidity and costs, the number of people with diabetes is still increasing in US and other countries. More than 29 million Americans are living with diabetes, and 86 million are living with prediabetes. Though the benefits of tight control of blood glucose have been well recognized still the management of diabetes is complex which demands for the more efficient standardized antidiabetic regimen.

US insulin market occupies more than 70% of the overall insulin market and is expected to grow significantly until 2022 owing to the growing number of individuals with diabetes. Factors such as better accessibility to treatment therapies and favorable reimbursement programs will result in the high turnout of patients opting for diabetes treatment, which in turn will boost the market's growth prospects in this region.

The US Antidiabetics Drug Market has seen a resurgence of activity in recent years with promising new products, such as ultra-rapid-acting and liver targeted insulin analogues, and insulin plus GLP-1 combinations in late stage development. Earlier stage candidates include several oral formulations, as well as ultra-long acting insulin analogues. Some ultra-long acting insulin analogues in development have the potential to greatly reduce the dosing frequency to just once weekly for basal insulin needs, as opposed to once daily.

In addition, the prospect of promising drugs in the pipeline, along with increasing awareness, is expected to contribute to the market's growth during the forecast period. The market is dominated by three key players: Eli Lilly, Novo Nordisk, and Sanofi. Novo Nordisk is the major vendor in the global insulin market. The largest product wise market revenue was generated by Lantus, which is marketed by Sanofi.

"US Antidiabetics Drug Market Outlook 2022" report highlights:

  • US Diabetes Epidemiology
  • US Antidiabetics Market Overview
  • Key Marketed Antidiabetic Drugs in US
  • US Biosimilar Insulin Market
  • US Antidiabetics Drug Market Future Prospects

Table of Contents

1. Antidiabetics: Regimen for Diabetes Mellitus

  • 1.1 Prologue Towards Diabetes
  • 1.2 Preface to Antidiabetics

2. Antiquity of Managing Diabetes Mellitus

  • 2.1 Trajectory from Diabetes to Insulin
  • 2.2 Historical En Route towards Oral Diabetic Medication

3. Treatments Available for Diabetes Mellitus

  • 3.1 Non-Pharmacological Approaches for Diabetes Mellitus
  • 3.2 Pharmacological Approaches for Diabetes Mellitus

4. Cataloguing of Antidiabetic Agents

  • 4.1 Antidiabetic: Oral Agents
    • 4.1.1 Biguanides
    • 4.1.2 Thiazolidinediones (TZDs)
    • 4.1.3 Sulfonylureas
    • 4.1.4 Meglitinides
    • 4.1.5 α- Glucosidase Inhibitors
    • 4.1.6 Dipeptidyl Peptidase-4 Inhibitor
    • 4.1.7 Bile Acid Sequestrants (BAS)
    • 4.1.8 Dopamine Agonist-2

5. Antidiabetic: Injectable Drugs

  • 5.1 Insulin: A life saving Modality
  • 5.2 Non-Insulin Alternatives for Diabetes Mellitus

6. US Diabetes Epidemiology

  • 6.1 Prevalence of Type 1 & 2 Diabetes
  • 6.2 Economic Burden Associated with Type 1 & 2 Diabetes: Productivity Loss & Medical Bills

7. US Antidiabetics Market Overview

  • 7.1 Antidiabetic Injectable Market Trends in US
  • 7.2 Antidiabetic Oral Drugs Market Trends in US
  • 7.3 Commending Trends of Antidiabetics

8. US: Key Marketed Antidiabetic Drugs

  • 8.1 Insulin Degludec (Tresiba)- Injection
  • 8.2 Insulin Lispro - Injection
  • 8.3 Insulin Inhalation(Afrezza) - Inhalation
  • 8.4 Insulin Glargine (Toujeo) - Injection
  • 8.5 Insulin Glulisine (Apidra) - Injection
  • 8.6 Insulin Aspart (NovoLog) - Injection
  • 8.7 Insulin Detemir (Levemir FlexTouch) - Injection
  • 8.8 Insulin Glargine (Lantus) - Injection
  • 8.9 Insulin Aspart/Insulin Protamine Aspart (NovoLog) - Injection

9. US Biosimilar Market: Glargine Basaglar - The First "Biosimilar" Insulin

  • 9.1 Overview
  • 9.2 Impact of Biosimilar Insulin

10. US Antidiabetics Drug Market Dynamics

  • 10.1 Accelerative Parameters
  • 10.2 Major Challenges

11. US Antidiabetics Drug Market Future Prospects

12. Competitive Landscape

  • 12.1 AstraZeneca
  • 12.2 Bayer
  • 12.3 Boehringer Ingelheim
  • 12.4 Eli-Lilly
  • 12.5 Johnson & Johnson
  • 12.6 Merck
  • 12.7 Novartis
  • 12.8 Novo Nordisk
  • 12.9 Sanofi
  • 12.10 Takeda

List of Figures

  • Figure 1-1: Illustration of the Categories of Diabetes Mellitus
  • Figure 1-2: Percentage of Different types of Antidiabetics Used
  • Figure 2-1: Historical Pathway of oral Diabetic Medication
  • Figure 3-1: Control of Glucose Uptake during Muscle Working
  • Figure 4-1: Categorization of Oral Antidiabetics Approved in US
  • Figure 4-2: Chemical Structure of Metformin, Phenformin & Buformin
  • Figure 4-3: Illustration of the Sub-Categories of Sulfonylureas
  • Figure 5-1: Mechanism of Insulin in Regulation of Blood Glucose Levels
  • Figure 5-2: Differences between Diabetes Mellitus 1 & 2 over Insulin
  • Figure 5-3: Structure of Differentiation of Peptidic Insulin Analogs
  • Figure 5-4: Demonstration of Action Profiles of Insulin Analogue
  • Figure 5-5: Activity Profiles of Different Types of Insulin
  • Figure 5-6: Difference between Lantus & Levemir
  • Figure 6-1: US: Number of Type 1 Diabetes Incidence (Million), 2016 & 2022
  • Figure 6-2: US: Number of Type 2 Diabetes Incidence (Million), 2014 - 2022
  • Figure 6-3: US: Type 1 Diabetes Prevalence Rate (%), 2016 & 2022
  • Figure 6-4: US: Type 2 Diabetes Prevalence Rate (%), 2014 - 2022
  • Figure 6-5: US: Diabetes Prevalence Rate among Adults Aged 18+ (%), 2010 - 2016
  • Figure 6-6: US: Obesity Rate Among Adults Aged 18+ (%), 2010 - 2016
  • Figure 6-7: US: Percentage of Adults with Obesity by State (%), 2015
  • Figure 6-8: Illustration of Total Cost of Diabetes Expenditure
  • Figure 6-9: Annual Average Cost Of Diabetes per Person in US
  • Figure 6-10: US: Productivity Loss Due To Type 1 Diabetes (US$ Billion), 2014 - 2022
  • Figure 6-11: US: Productivity Loss Due To Type 2 Diabetes (US$ Billion), 2014 - 2022
  • Figure 6-12: US: Medical Cost for Type 1 Diabetes (US$ Billion), 2014-2022
  • Figure 6-13: US: Medical Cost for Type 2 Diabetes (US$ Billion), 2014-2022
  • Figure 7-1: Overview of Diabetic Drug Market Segmentation
  • Figure 7-2: US: Antidiabetics Drug Market (US$ Billion), 2014 - 2022
  • Figure 7-3: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$ Billion), 2016
  • Figure 7-4: US - Percentage of Most Common Class of Antidiabetics Drugs
  • Figure 7-5: US - Percentage of Generally Prescribed Anti-Diabetic Drugs (%)
  • Figure 8-1: US - Insulin Degludec (Tresiba) Injection Sales (US$ Million), 2016-2022
  • Figure 8-2: US -Insulin Lispro Injection Sales (US$ Million), 2016-2022
  • Figure 8-3: US - Insulin Glargine (Toujeo) Injection Sales (US$ Million), 2016-2022
  • Figure 8-4: US - Insulin Glulisine (Apidra) Injection Sales (US$ Million), 2016-2022
  • Figure 8-5: US - Insulin Detemir (Levemir FlexTouch) Injection Sales (US$ Million), 2016-2022
  • Figure 9-1: Major Accelerative Parameters for Antidiabetic Market in US
  • Figure 9-2: Estimated Impact of Increasing Trend in Obesity by 2020
  • Figure 9-3: Estimated Increase in Total Number with Diagnosed Diabetes till 2050
  • Figure 9-4: Major challenges in Antidiabetics Market
  • Figure 9-5: Important Challenges with the Use of Insulin
  • Figure 10-1: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$ Billion), 2022
  • Figure 10-2: Illustration of Antidiabetic Drugs Under Development
Back to Top